Placeholder Banner

BIO Comments on FDA Draft Guidance on Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics

July 8, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry.

BIO welcomes the draft guidance, which establishes a simple and reliable mechanism for identifying submissions with Real-World Data – a new area of regulatory science and policy at FDA.

BIO encourages FDA to consider how Real-World Data (RWD) or Real-World Evidence (RWE) could be used to generate publicly available information, like public summaries, for the research community. BIO also comments on document submissions for Investigational New Drugs (INDs), New Drug Applications (NDAs), or Biologics License Applications (BLAs). Finally, BIO’s provides recommendations on how to better promote the collection and utilization of RWD or RWE.

 

Download Full Comments Below
FINAL BIO Letter Submitting Documents Using RWE 7-8-19
Read the full comments below
Discover More
February 14, 2020 Re: Docket No. FDA–2020-D-0529: FDA Draft Guidance, Qualification Process for Drug Development Tools Dear Sir/Madam:  The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency)…
February 11, 2020 Re: Docket No. FDA–2019-D-4751: Food and Drug Administration Reauthorization Act Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs Dear Sir/Madam: The Biotechnology Innovation Organization (BIO…
February 3, 2020 Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments regarding FDA’s public workshop on Patient-Focused Drug Development…